Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Amplia TherapeuticsASX:ATX +3.70%30 EV-to-EBITDA is -5.84 as of Jul. 26, 2026. GuruFocus rates ASX:ATX with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 404 Biotechnology companies, Amplia Therapeutics ranks worse than 247524.5% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Amplia Therapeutics's enterprise value is A$44.35 Mil.
Amplia Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was A$-7.60 Mil. Therefore, Amplia Therapeutics's EV-to-EBITDA for today is -5.84.
The historical rank and industry rank for Amplia Therapeutics's EV-to-EBITDA or its related term are showing as below:
ASX:ATX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -73.09 Med: 1.47 Max: 1.94
Current: -5.84
During the past 13 years, the highest EV-to-EBITDA of Amplia Therapeutics was 1.94. The lowest was -73.09. And the median was 1.47.
ASX:ATX's EV-to-EBITDA is ranked worse than 100% of 404
companies
in the Biotechnology industry
Industry Median: 11.82
vs ASX:ATX: -5.84
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Amplia Therapeutics's PE Ratio (TTM) for today is calculated as:
Amplia Therapeutics's share price for today is A$0.14.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Amplia Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was A$-0.017.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Amplia Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:ATX vs VRTX, REGN, ALNY: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Amplia Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amplia Therapeutics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Amplia Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Amplia Therapeutics's EV-to-EBITDA falls into.
Amplia Therapeutics's current Enterprise Value is A$44.35 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Amplia Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was A$-7.60 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amplia Therapeutics (ASX:ATX) has a EV-to-EBITDA of -5.84 as of Jul. 26, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Amplia Therapeutics. According to the industry distribution chart, Amplia Therapeutics ranks #999999 out of 404 companies in the Biotechnology industry.
Is Amplia Therapeutics' EV-to-EBITDA too high?
Amplia Therapeutics' current EV-to-EBITDA is -5.84. Based on the distribution chart, Amplia Therapeutics ranks #999999 out of 404 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Amplia Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Amplia Therapeutics' EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Amplia Therapeutics ranks #999999 out of 404 companies for EV-to-EBITDA. This places Amplia Therapeutics in the lower half of its industry. The industry median EV-to-EBITDA is 11.82. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 11.82, based on 404 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Amplia Therapeutics. For the Biotechnology industry, the median EV-to-EBITDA is 11.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amplia Therapeutics's current EV-to-EBITDA is -5.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amplia Therapeutics stock overvalued right now?
Amplia Therapeutics (ASX:ATX) has a current EV-to-EBITDA of -5.84. The current EV-to-EBITDA is -5.84. Amplia Therapeutics' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Amplia Therapeutics (ASX:ATX), the current EV-to-EBITDA is -5.84 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Amplia Therapeutics Ltd is an Australian, clinical-stage, drug development company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company is focused on the development of these drug candidates for potential use in multiple indications in oncology (e.g. pancreatic cancer) and chronic fibrotic diseases. Its molecule, AMP945 is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and preclinical development for idiopathic pulmonary fibrosis (IPF).
30GF Score
Get the complete analysis for ASX:ATX
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ATX has been successfully added to your 
